BBR selectively inhibits HFD-induced MTTP methylation to partially counteract HFD-induced MTTP dysregulation, which promotes normal levels of VLDL secretion in the liver, thereby reducing hepatic fat content and alleviating NAFLD (Chang et al., 2010). The gene discussed is MTTP; the disease is metabolic dysfunction-associated steatotic liver disease.